[GPIIb-IIIa inhibitors].

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Anti-glycoprotein (GP) IIb-IIIa inhibitors represent an evolution in treating percutaneous coronary intervention and acute coronary syndromes.
• These agents demonstrate a reduced risk of death or myocardial infarction compared to aspirin alone.

Purpose of the Study:

• To review the evolution, mechanisms, and clinical applications of anti-GP IIb-IIIa inhibitors.
• To discuss the differences between monoclonal antibody fragments and synthetic peptides, their binding specificities, and pharmacokinetic profiles.
• To address potential complications such as bleeding and thrombocytopenia, and strategies for management and readministration.

Main Methods:

• Review of existing literature on anti-GP IIb-IIIa inhibitors.
• Comparison of different classes of inhibitors: abciximab, eptifibatide, and tirofiban.
• Discussion of clinical outcomes, adverse events, and ongoing research.

Main Results:

• Anti-GP IIb-IIIa therapy significantly lowers mortality and myocardial infarction rates.
• Abciximab has a long half-life and binds to both GP IIb-IIIa and vitronectin receptors, while eptifibatide and tirofiban are shorter-acting peptides binding only to GP IIb-IIIa.
• Bleeding risk can be mitigated by careful heparin management and early sheath removal.
• Thrombocytopenia is a potential complication, though its cause is under investigation.
• Readministration of abciximab is being explored with initial promising results.

Conclusions:

• Anti-GP IIb-IIIa inhibitors are effective in managing acute coronary syndromes and during percutaneous coronary intervention.
• Careful patient management is crucial to minimize bleeding complications.
• Further research is needed to optimize the use and monitoring of these potent anti-platelet agents, including the development of point-of-care tests.